Neospora caninum calcium-dependent protein kinase 1 is an effective drug target for neosporosis therapy. by Ojo, Kayode K et al.
Neospora caninum Calcium-Dependent Protein Kinase 1
Is an Effective Drug Target for Neosporosis Therapy
Kayode K. Ojo1*, Molly C. Reid1, Latha Kallur Siddaramaiah2, Joachim Mu¨ller3, Pablo Winzer3,
Zhongsheng Zhang2, Katelyn R. Keyloun1, Rama Subba Rao Vidadala4, Ethan A. Merritt2, Wim G. J. Hol2,
Dustin J. Maly4, Erkang Fan2, Wesley C. Van Voorhis1*, Andrew Hemphill3*
1Center for Emerging and Re-emerging Infectious Diseases (CERID), Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington,
Seattle, Washington, United States of America, 2Department of Biochemistry, University of Washington, Seattle, Washington, United States of America, 3 Institute of
Parasitology, Vetsuisse Faculty, University of Berne, Berne, Switzerland, 4Department of Chemistry, University of Washington, Seattle, Washington, United States of
America
Abstract
Despite the enormous economic importance of Neospora caninum related veterinary diseases, the number of effective
therapeutic agents is relatively small. Development of new therapeutic strategies to combat the economic impact of
neosporosis remains an important scientific endeavor. This study demonstrates molecular, structural and phenotypic
evidence that N. caninum calcium-dependent protein kinase 1 (NcCDPK1) is a promising molecular target for neosporosis
drug development. Recombinant NcCDPK1 was expressed, purified and screened against a select group of bumped kinase
inhibitors (BKIs) previously shown to have low IC50s against Toxoplasma gondii CDPK1 and T. gondii tachyzoites. NcCDPK1
was inhibited by low concentrations of BKIs. The three-dimensional structure of NcCDPK1 in complex with BKIs was studied
crystallographically. The BKI-NcCDPK1 structures demonstrated the structural basis for potency and selectivity. Calcium-
dependent conformational changes in solution as characterized by small-angle X-ray scattering are consistent with previous
structures in low Calcium-state but different in the Calcium-bound active state than predicted by X-ray crystallography. BKIs
effectively inhibited N. caninum tachyzoite proliferation in vitro. Electron microscopic analysis of N. caninum cells revealed
ultra-structural changes in the presence of BKI compound 1294. BKI compound 1294 interfered with an early step in
Neospora tachyzoite host cell invasion and egress. Prolonged incubation in the presence of 1294 interfered produced
observable interference with viability and replication. Oral dosing of BKI compound 1294 at 50 mg/kg for 5 days in
established murine neosporosis resulted in a 10-fold reduced cerebral parasite burden compared to untreated control.
Further experiments are needed to determine the PK, optimal dosage, and duration for effective treatment in cattle and
dogs, but these data demonstrate proof-of-concept for BKIs, and 1294 specifically, for therapy of bovine and canine
neosporosis.
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Introduction
The apicomplexan parasite, Neospora caninum, is the leading
cause of epidemic abortion in cattle and is also a frequent cause of
neuromuscular diseases in dogs. A recent estimate of neosporosis-
induced abortions in cattle from Argentina, Australia, Brazil,
Spain, Canada, Mexico, New Zealand, United Kingdom and the
USA suggests an annual economic impact in excess of 1.2 billion
USD [1]. N. caninum related diseases have also been reported in
other livestock species, including sheep, goats, horses and deer
[2],[3] with canids such as dogs, wolves and coyotes being the
definitive hosts [4],[5]. Therefore, neosporosis represents a major
veterinary health and economic concern. Neoguard, a killed
tachyzoite lysate and the only vaccine that has been marketed to
date, was reported in one publication to reduce the abortion rate
in cattle by approximately 50% [6] but does not induce protection
against fetal infection in cattle. However, more recent trials
revealed fewer efficacies in the field, and even suggested that
vaccination may increase the risk of early embryonic death [7].
Thus, the vaccine has been taken off the market. The application
of live attenuated vaccines, although potentially more efficacious,
carries the risk of early embryonic death as a result of potential
reversion to virulence [7]. Chemotherapy could provide a viable
alternative if appropriate compounds are identified. Both in vivo
and in vitro studies have been performed to determine efficacy of
treatments with lasalocid, monensin, pirithrexim, pyrimethamine,
clindamycin, robenidine and trimethoprim [8], artemisinin and
artemisone [9], [10], depudecin [11], toltrazuril, and ponazuril
[12] although none of these studies showed that treatments were
actually effective in cattle. To date there is no approved vaccine
and no approved treatment for cattle that are infected with N.
caninum.
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A study on prophylactic administration of toltrazuril in newborn
calves suggests some degree of protection based on serological
response data [13], but protection has never been proven.
Treatment with prolonged administration of clindamycin or
potentiated sulfa drugs (in combination with trimethoprim) were
only successful in eliminating clinical signs in less than 40% cases
of canine neosporosis [14]. Clearly, a new and more efficacious
therapeutic is needed to reduce the economic impact of
neosporosis on farmers and the global economy. We recently
demonstrated that apicomplexan calcium-dependent protein
kinases (CDPKs) are promising drug targets, as observed from
excellent correlations between cell-activity and enzyme inhibition
by compounds from a focused bumped kinase inhibitor (BKI)
library as well as chemical-genetic validation [15–17]. Toxoplasma
gondii CDPK1 (TgCDPK1) (TGME49_101440) has been reported
to be associated with host cell invasion processes [15], [18].
TgCDPK1 has the smallest possible gatekeeper amino acid in the
ATP binding site, glycine. Most BKIs have bulky C3 aryl
substituents that project into a hydrophobic pocket adjacent to
the glycine gatekeeper in the ATP binding site. BKIs selectively
inhibit TgCDPK1 but don’t inhibit mammalian kinases because
mammalian kinases have larger gatekeeper residues that block the
entry of the bulky C3 aryl substitution into the adjacent
hydrophobic pocket. N. caninum is similar to T. gondii in its ability
to invade a large variety of cells [19–21] and their genomes are
highly similar as well. The two parasites share a conserved core
proteome, similar core biochemical processes, and 99% CDPK1
amino acid sequence identity including a glycine gatekeeper
residue. Thus, it seems likely that BKIs, which efficiently inhibit
host cell invasion in T. gondii, will also block N. caninum invasion
and growth. However, it is necessary to test the function of
NcCDPK1 as divergence of functions or pathways may have
occurred.
In this report, we describe the biochemical, structural, and
biophysical aspects of NcCDPK1 enzyme and the nanomolar
potency of BKIs in the inhibition of NcCDPK1. The effect of BKI
inhibitors on N. caninum tachyzoite proliferation and development
were determined. Seven of the tested BKIs exhibit low-to-mid
nanomolar activity against N. caninum proliferation in vitro, making
them good candidates for therapeutic investigation. A therapeutic
oral trial with a BKI, 1294, demonstrated marked reduction of N.
caninum cerebral parasite burden in mice, thus demonstrating
proof-of-concept for neosporosis therapy. Thus, our studies define
a strategy for the development of potent and safe NcCDPK1
inhibitors that could form the basis of a novel neosporosis
treatment regimen.
Results
In vitro activity of BKIs against NcCDPK1 enzyme activity
and N. caninum proliferation
The potency of 8 BKIs against recombinant NcCDPK1 kinase
activity was evaluated. Seven of the BKI compounds inhibited
NcCDPK1 enzyme with IC50 in the range of 1.2 to 2.6 nM, while
one of them, BKI 1266 [16], had a much higher IC50 at 513 nM
(Figure 1). The observed IC50 values are closely related to
previously published TgCDPK1 inhibition data for these same
compounds [22]. The EC50 values of the inhibitors to block N.
caninum growth were determined. The seven BKIs with 1 to 3 nM
IC50s for inhibiting NcCDPK1 enzyme activity inhibit the growth
of N. caninum tachyzoites in vitro with EC50 values in the range of 49
to 140 nM. Compound 1266 [16], with the higher IC50 of
513 nM, was unable to block N. caninum proliferation in vitro, even
at the highest concentration tested (2500 nM). Though there are
not many BKIs tested yet, there is a good correlation between
potency in vitro towards NcCDPK1 inhibition and N. caninum
growth. None of these compounds showed mammalian cell
cytotoxicity when assayed against human lymphoblastoid cell,
CRL 8155, and none had off-target inhibition of small gatekeeper
(threonine) human protein kinases [22]. Our data shows 1294
(Figure 1) had a 2.6 nM IC50 against NcCDPK1 enzyme and
32 nM EC50 against N. caninum tachyzoites. Compound 1294 has
previously been reported to exhibit profound in vitro and in vivo
activity against Cryptosporidium parvum [17] cell growth and have
excellent malaria transmission blocking properties [23]. Pharma-
cokinetic data with 1294 demonstrates favorable absorption with
low clearance, supporting daily oral administration, and low
toxicity in mammalian cells and rodents [23]. Efficacy against N.
caninum tachyzoites in cell culture points to another anti-
apicomplexan application for 1294 justifying it for broad spectrum
drug development.
Crystallographic confirmation of inhibitor binding modes
NcCDPK1 is 96% sequence identical to the well-studied
TgCDPK1. The active site environment of NcCDPK1 differs at
only amino acid position 123 having tyrosine rather than
phenylalanine at TgCDPK1 residue 124. This change does not
alter the binding surface in the active site, but may act to slightly
rigidify the active site conformation by introducing a new
hydrogen bonding interaction between residues Tyr 123 and
Glu 88. The observed binding pose of the pyrazolopyrimidine (PP)
scaffold and the R1 substituent ‘‘bump’’ in the inhibitor complexes
studied here is entirely consistent with that seen previously for PP-
scaffold inhibitors bound to the T. gondii homolog (Figure 2A,
Figure S1 and S2 in File S1). Compound 1266 [16] is
approximately 200 fold less effective at inhibiting CDPK1s relative
to other BKIs shown in the study probably due to its distinctive
quinoxaline R1 ring system rather than the common naphthalene,
quinoline, or isoquinoline R1 group. A three-dimensional (3-D)
model of CDPK1 with 1266 predicted that the quinoxaline
nitrogen at position 9 (N9) is oriented toward the carbonyl oxygen
of residue valine 78 (3.3 A˚ distance). This would have been quite
favorable for additional hydrogen bonding if the N9 was
hydrogen. However, a quinoxaline nitrogen may not have a
proton at pH values above 1, making this an unfavorable
interaction because the carbonyl oxygen of residue valine 78
and the N9 pay a price in solvation energy by facing each other
rather than solvent waters. Data from this study confirmed that the
model for the structural basis of potency and specificity developed
for the optimization of potential anti-toxoplasmosis drugs based on
this scaffold is also applicable to optimization of anti-neosporosis
drugs [22], [24]. The pose of the piperidine R2 substituent in the
current structures is similar but not identical to that seen in
TgCDPK1 complexes with other inhibitors containing piperidine
ring substituents at this position, which in turn are not identical to
each other. This argues for flexibility in the orientation of the
piperidine substituents even after binding of these nanomolar
inhibitors, and allows additional chemical modifications of this
group if necessary to further optimize PK/AMDET properties.
Ca2+-dependent conformational state in solution
The structure of NcCDPK1 as seen in both the apo and
inhibitor-bound crystals is consistent with the ‘‘inactive’’ forms
previously seen in calcium-free crystal structures of CDPK1
homologs from C. parvum (ApiDB_CryptoDB:cgd3_920) and T.
gondii (TGME49_101440). In this conformational state the C-
terminal Ca2+-binding domain forms a compact structure that
occludes the active site of the N-terminal kinase domain, thus
Neospora caninum CDPK1 Is an Effective Drug Target
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Figure 1. In vitro activity of BKIs against NcCDPK1 activity and N. caninum proliferation. +IC50 represents the concentration that inhibits
protein kinase activity by 50%. *EC50 represents the concentration that inhibits cell growth by 50%.
doi:10.1371/journal.pone.0092929.g001
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preventing the recognition or phosphorylation of substrate
proteins. Intracellular regulation of CDPK activity is believed to
be mediated by a radical conformational rearrangement that
occurs in the presence of sufficiently high concentrations of Ca2+.
This is supported by previous crystal structures of calcium-bound
states of C. parvum and T. gondii homologs [25], but direct
measurement of CDPK conformational states in solution has not
been previously reported. Therefore we undertook characteriza-
tion of the low- and high- (Ca2+) conformational states of
NcCDPK1 in solution using small angle X-ray scattering (SAXS).
As predicted from crystal structures of the low and high calcium
conformations of TgCDPK1, the solution X-ray scattering profiles
for NcCDPK1 in the two states are significantly different, as are the
derived conformational models (Figure 2B). However while there
is good agreement between the SAXS and crystallographic models
for the low-(Ca2+) state, both the radius of gyration and the
envelope of the SAXS reconstruction indicate a high-(Ca2+) state
in solution that is less compact than was captured in previous
crystal structures of homologous CDPKs with bound calcium.
The scattering profile for the low-(Ca2+) state in solution
indicates a 29.162.3 A˚ radius of gyration (Rg). Direct reconstruc-
tion of the implied conformational state is consistent with the low-
(Ca2+) state seen in the current NcCDPK1 crystal structures and
with the previously reported calcium-free crystal structures of
CDPK1 homologs. This agreement is also shown by the good
correlation cc = 0.88 between the observed scattering curve and
the curve predicted from the apo NcCDPK1 crystal structure. The
scattering profile for the high-(Ca2+) state in solution indicates a
radius of gyration Rg = 35.161.8 A˚, significantly larger than that
observed for the low-(Ca2+) state. Direct reconstruction of the
implied high-(Ca2+) conformational state in solution yields a model
that is distinctly different from the reconstruction of the low-(Ca2+)
state. The correlation between the observed scattering curve and
that predicted from a crystal structure of the homologous calcium-
bound TgCDPK1 (PDB 3hx4) is cc = 0.83.
The most likely explanation for the less compact state observed
for the high-(Ca2+) conformation of NcCDPK1 as measured in
solution when compared to that of TgCDPK1 as seen in a crystal is
that in solution the rearranged secondary structural elements of
the Ca2+-binding domain exhibit sufficient flexibility for the
protein to adopt a range of conformational states. Only a single
relatively compact state from this range is favored, or stabilized,
during formation of the crystal lattice. An equivalent discrepancy
between the observed crystalline and solution states of the calcium-
binding motifs in calmodulin is well-known [26]. It is also possible,
although less likely, that there is a true difference between the
calcium-bound states of TgCDPK1, for which there is crystallo-
graphic data, and NcCDPK1, for which there is only SAXS data.
There are three sequence differences between NcCDPK1 and
TgCDPK1 in the calcium-binding domain that might hypothet-
ically influence the dynamics of the calcium-bound state. These
two possible explanations are not mutually exclusive.
Compound 1294 prevents N. caninum tachyzoite host
cell invasion
In T. gondii, it has been postulated that the activity of BKIs is
based on the inhibition of serine threonine kinase CDPK1
phosphorylation activity needed in part to regulate intracellular
calcium induced activation of the glideosome system and apical
secretion of micronemal transmembrane adhesins which engage
the motor complex for successful invasion of the host cells [15],
[27]. Analysis of N. caninum growth and proliferation when treated
with compound 1294 over an infection time course of 2 hours
suggests that it severely impairs the host cell invasion process
(Figure 3A). Its greatest impact is associated with the early stage of
the host cell-parasite interaction. When 1294 was added to
cultures at the timepoint where HFF infection with N. caninum
tachyzoites was initiated, and incubated for 2 hours before
removal by washing, there was a significant decrease in beta-
galactosidase activity compared to experiments where compound
1266 [16] (negative, low-potency control) or DMSO were assessed
(t-test; p,0.001) (Figure 3A). With subsequent addition of 1294 at
Figure 2. a: Binding pose of pyrazolopyrimidine analogues in
complexes NcCDPK1. The crystallographically observed binding
poses of inhibitors RM-1-132 (15n) and 1294 (15o). The bulky
naphthalene substituent is accommodated by the presence of a small
(glycine) gatekeeper residue. The piperidine substituents extend into
the ribose binding pocket of the kinase active site. The pose and
interactions of the PP scaffold with the protein backbone are highly
consistent for members of this series of BKI compounds 24. b:
Conformational states of NcCDPK1 in solution using SAXS. The SAXS
profiles measured for the low calcium (green) and high calcium (black)
states of NcCDPK1 in solution. The inset shows the corresponding low
resolution 3D models generated from the respective profiles, superim-
posed onto crystal structures of the low calcium state of NcCDPK1 (this
work; PDB 4m97) and a high calcium state of TgCDPK1 (PDB 4hx4). The
crystallographic and SAXS models agree better for the low calcium state
(left) than for the high calcium state (right). The model for the high
calcium state derived from the observed SAXS profile (gray solid) is
more extended, i.e. has a larger radius of gyration, than the crystal
structure.
doi:10.1371/journal.pone.0092929.g002
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60, 90 and 115 minutes after initiation of HFF infection, there was
no significant difference in beta-galactosidase activity, and no
difference could be seen when 1294 was added after the infection
phase of 2 hours had ended (p.0.2). SEM of HFF monolayers
infected with N. caninum tachyzoites either in the presence or
absence of compound 1294 (Figure 3B–D) and subsequently
maintained in the presence of 1294 for 3 days showed that
proliferation of parasites was markedly inhibited when the
compound was added during the infection phase, but not when
1294 was added after infection has taken place. In other
experiments involving in vitro 1294 treatment of infected HFF for
up to 12 days, however, we could show that the effects mediated
by 1294 are not only restricted to the inhibition of host cell entry.
Continuous inspection by light microscopy showed that intracel-
lular N. caninum tachyzoites did initially undergo proliferation in
the presence of 2.5 mM 1294, but lysis of host cells was evident
only in a few instances. However, from day 5 post infection
onwards in the presence of 2.5 mM 1294, no extracellular
tachyzoites were visible (data not shown). To assess whether any
viable parasites remained, after 12 days of continuous 1294
treatment the infected HFF cultures were trypsinized and were
further cultivated with a fresh monolayer in the absence of
compound 1294. Some tachyzoites resumed proliferation and host
cell lysis occurred again within 3 days, leading to complete lysis of
monolayers within one week (data not shown). This indicated that
the interference of compound 1294 with N. caninum development
was not completely parasiticidal under the conditions used in this
experiment. However, this experiment was not quantitative and
did not distinguish whether a substantial fraction of the parasites
were non-viable. To understand if the parasites were damaged by
exposure to 1294 once intracellular, we initiated the following
ultrastructural experiments.
Effects of compound 1294 on N. caninum tachyzoite
ultrastucture
TEM analysis of N. caninum infected HFF cultures confirmed
that the effects of 1294 were not entirely restricted to invasion
inhibition, but that at a concentration of 2.5 mM the compound
also interfered in the intracellular development of N. caninum
tachyzoites with no observable evidence of damage to the
mammalian host cells. When the inhibitor was added at the time
point of infection, basically no intracellular tachyzoites could be
observed by TEM, and HFF morphology remained unaltered,
confirming that compound 1294 did not affect the host cells but
rather blocked tachyzoite invasion (Figure 3D, 4A and B).
Transmission electron micrographs of untreated and N. caninum-
infected host cells at 3 days after invasion are shown (Figure 4C
and D). Tachyzoites are located within parasitophorous vacuoles
(PVs), of varying sizes depending on the number of tachyzoites
present, and they are separated from the cytoplasm by a
parasitophorous vacuole membrane (PVM), and embedded in a
tubular membrane network (PVTN).
When the compound was applied 2 hours after tachyzoites
achieved host cell entry, a variety of effects can be visualized
already after 3 days of treatment. On one hand, we observed
parasitophorous vacuoles containing numerous and densely
packed tachyzoites similar to the ones observed in untreated
cultures (Figure 5A and B), indicating that the compound did not
have any profound effects on the intracellular development of N.
caninum tachyzoites. However, in many instances, vacuoles were
seen that contained parasites with an enlarged cytoplasmic mass
and aberrant overall morphology (Figure 5C and D), and also
vacuoles containing typically a lower number of parasites
exhibiting signs of metabolic impairment such as cytoplasmic
vacuolization and electron-dense inclusions (Figure 5E and F).
More pronounced alterations were visible at day 5 of drug
treatment (Figure 6). On one hand, largely destroyed parasites
were observed intracellularly, located still within a parasitophorous
vacuole, but the matrix of this vacuole was becoming electron
dense and granular in appearance, and the parasitophorous
vacuole membrane was not clearly discernible anymore (Figure 6A
and B). On the other hand, numerous infected HFF contained
complexes of still viable and presumably proliferating, but non-
separating, parasites forming a large multi-nucleated mass within a
parasitophorous vacuole clearly delineated and separated from the
host cell cytoplasm by a membrane. Interestingly these complexes
often contained several smaller nuclei in addition to an outstand-
ingly enlarged nucleus with a respectively enlarged nucleolus
(Figure 6C). The two contrasting phenomena were sometimes seen
within the same host cell (Figure 6A). At day 9 of 1294 treatment,
these multinucleated complexes increased in size, and the matrix
of the parasitophorous vacuole has completely lost the character-
istics of a tubular membranous network and was replaced by
components of more granular and vesicular appearance (Figure 6D
and E). In many instances, however, the ultrastructure of these
parasite complexes was severely damaged and only residual, non-
viable complexes were seen, located within an electron-dense
matrix. Under the conditions used here, the cultures were
completely lysed at time points later than day 4, so it was
impossible to show a control, because this will contain mostly
extracellular (and dying) parasites. Taken together, these results
clearly indicate that compound 1294 does not only affect host cell
invasion, but that this compound does also interfere in separation
of zoites once nuclear division and cytoplasmic duplication has
taken place, resulting in the appearance of large, multi-nucleated
masses, which are, however, still viable. Once the compound is
removed, these effects are most likely reversible, and division of
tachyzoites proceeds, resulting in lysis of the host cells.
Effects of 1294 on N. caninum infected Balb/c mice
In the murine experimental model of infection, as expected,
none of the mice showed abnormal behavior or clinical signs of
neosporosis during the entire 28 days of experiment. Treatment
with 1294 led to a reduction of the cerebral parasite load in mice
previously infected by N. caninum as determined by quantitative
RT-PCR (shown in Figure 7). Cerebral parasite burdens in the
different groups were analyzed by ANOVA after logarithmic
transformation of the original data. ANOVA revealed that values
from at least one group were statistically different from another
(p,0.01) followed by post-hoc test according to Bonferroni to
compare the groups B and C to the control group A. Amongst the
2 experimental treatment regimens, the one applied to group C
(1294 therapy starting on day 3 post infection and continued for 10
days) was clearly the most effective (P= 0.0047). Treatment group
B (treatment as in C but only for 5 days) also showed a tendency
towards reduced parasite load (P= 0.0139). Treatment of 1294 did
not inhibit infection of the brain completely. Nevertheless, the
degree of efficacy in this model of infection was particularly
significant when considering that treatment with 1294 was
discontinued .2 weeks before the end of the experiment and
collection of the brains for qPCR and yet minimal numbers of
parasites were observed in the treated groups (Figure 7).
Discussion
Toxoplasma gondii and Neospora caninum are obligate intracellular
parasites that must invade the host cell to grow and replicate.
Proliferation occurs after successful invasion of a host cell by a
Neospora caninum CDPK1 Is an Effective Drug Target
PLOS ONE | www.plosone.org 5 March 2014 | Volume 9 | Issue 3 | e92929
complex process of coordinated secretion of proteins regulated in
part by changes in intracellular calcium concentrations. Cell
invasion, in this case, is independent of host calcium control
systems but relies on a calcium-regulated secretion pathway in the
parasite [28], [29] directed in part by CDPKs. This points to an
autonomous system with heavy reliance on the parasites’ intrinsic
factors, an intriguing opportunity for anti-apicomplexan specific
chemotherapy. Toxoplasma gondii calcium-dependent protein kinase
1 (TgCDPK1) has generated increasing interest in recent years
because of its essential physiological roles and as a potential drug
development target [15], [22], [30–32]. A high degree of amino
acid sequence and structural similarities between Toxoplasma gondii
and Neospora caninum CDPK1 enzymes and the high degree of
conservation between T. gondii and N. caninum genomes suggests
that both enzymes have similar functional characteristics. By
extrapolating from TgCDPK1 functional characteristics, it would
be anticipated that inhibitors of NcCDPK1 would be sufficient to
interrupt the growth and proliferation of N. caninum tachyzoites by
preventing host cell invasion and/or egress. Nonetheless, potential
functional divergence between TgCDPK1 and NcCDPK1 com-
bined with the distinct range of mammalian host systems in which
the parasites operate warrants detailed understanding of possible
differences in their molecular structure and specific phenotypic
response to their inhibition by BKIs.
This study presents the first crystal structures of parasitic
protozoan N. caninum CDPK1 enzyme. The inhibitor structure-
activity relationships (SARs) of NcCDPK1 and TgCDPK1 for all
compounds tested are virtually identical (Figure 1) [22] suggesting
that similar BKIs could be useful for both toxoplasmosis and
neosporosis therapy. This observation supports our inhibitor-
binding mode model derived from BKIs-Tg/NcCDPK1-complex
crystal structures that shows favorable interaction of the C3 aryl
bump with the gatekeeper hydrophobic pocket (Figure 2A, Figure
S1 and S2 in File S1). Earlier observations strongly suggest that the
vicinity of the ribose pocket can serve as an additional potency and
selectivity-determining region especially in BKI analogues with a
piperidine R2 group [22], [24]. However, NcCDPK1 has a similar
but not identical pose as the piperidine R2 substituent in the ribose
pocket relative to TgCDPK1 (Figure 2A, Figure S1 and S2 in File
S1). Furthermore the small-angle X-ray scattering (SAXS) analysis
Figure 3. Compound 1294 interferes in host cell invasion. (A) Measurement of b-galactosidase activities in HFF during the invasion process.
HFF monolayers were infected by incubating them with 26104 N. caninum (b-Gal) tachyzoites for 2 hours. Prior to this 2 hour invasion phase
(timepoint 09), tachyzoites were suspended either in DMSO (DMSO 09), in 5 mM compound 1266 (1266 09) or in 5 mM 1294 (1294 09). In additional
assays, compound 1294 was added at 60 min after initiation of invasion (1294 609), 90 min (1294 909) or 115 min (1294 1159) prior to removal of the
drug by washing. Cultures were then incubated for an additional 60 min before b-galactosidase activity was measured. There was a significant
decrease in b-galactosidase activity (t-test; p,0.001) when compound 1294 was added at the beginning of infection (1294 09), but not when the
compound was added at later timepoints, and no changes occurred when 1294 was added after the infection phase (1294 609 post-infection. (B–D)
Scanning electron micrographs of HFF infected with N. caninum for 3 days. Cultures were maintained in the absence of 1294 (B), in the presence of
2.5 mM 1294 added 2 h post-invasion (C), and in the presence of 2.5 mM 1294 added already at the time point of invasion (D). Cultures were
processed for SEM analysis after 3 days. Note the presence of parasitophorous vacuoles in B and C (arrows), and respective absence in D.
doi:10.1371/journal.pone.0092929.g003
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presented in this study constitutes the first direct characterization
of the calcium-responsive conformational rearrangement of
CDPK1 in solution. As previously found for the structurally
similar calcium-binding domain of calmodulin, the calcium-bound
form of CDPK1 observed in solution is less compact than the
calcium-bound form of the same protein observed crystallograph-
ically. The implied multiplicity of calcium-bound states is entirely
compatible with our understanding of the mechanism of calcium-
regulated kinase activity, in which the calcium-induced rearrange-
ment displaces structural elements that limit access to the active
site. However it indicates that previous crystal structures of
CDPK1 calcium-bound states do not represent a single biologi-
cally active conformation present in solution. By contrast, the
SAXS profile for the calcium-free state in solution is consistent
with the crystal structures of the calcium-free state of TgCDPK1
and NcCDPK1 used to interpret structure-activity relationships.
Figure 4. TEM analysis of compound 1294 treated and untreated N. caninum-infected HFF cultures at 3 days post-infection. A shows
a HFF cell with inhibitor 1294 (2. 5 mM) added at the time point of infection, B represents a higher magnification view of A. Note the absence of
parasites, and the fact that compound 1294 does not induce any obvious ultrastructural alterations within the host cell. C and D show N. caninum-
infected HFF cultured in the absence of the inhibitor at 3 days post-invasion. Numerous tachyzoites are located within parasitophorous vacuoles,
surrounded by a parasitophorous vacuole membrane (PVM), and embedded in a matrix of a tubular membrane network (PVTN). Apical parts of
tachyzoites are characterized by the conoid (con), micronemes (mic), and rhoptries (rho); dg = dense granules, nuc = tachyzoite nucleus, hcnuc =
host cell nucleus. The two arrows in C point towards proliferating tachyzoites undergoing endodyogeny. Bars in A = 5 mm; B= 1 mm; C= 0.58 mm;
D= 0.28 mm.
doi:10.1371/journal.pone.0092929.g004
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Figure 5. TEM analysis of N. caninum-infected HFF cultures treated for 3 days, with 2.5 mM of inhibitor 1294 added at 2 h post-
infection. A and B show micrographs of more or less densely packed parasitophorous vacuoles containing numerous tachyzoites without obvious
alterations. C and D show a representative example of a vacuole delineated by a parasitophorous vacuole membrane (pvm) containing parasites
displaying a large cytoplasmic mass and aberrant overall morphology. The boxed area in C is enlarged in D, exhibiting the presence of the pvm and
rhoptry-like organelles (rho). In many instances, as seen in Figure 5E and F, parasitophorous vacuoles contain several parasites exhibiting clear signs
of metabolic impairment such as cytoplasmic vacuolization (vac) and electron-dense inclusions (inc). (Figure 5E, F). Note that in C–F the matrix has
lost its characteristic tubular network structure and is now formed of either granular material or possibly membranous material (C, D), or is even
largely missing (E. F). Bars in A= 1 mm; B= 0.9 mm; C= 0.75 mm, D= 0.35 mm; E = 0.3 mm; F = 0.3 mm.
doi:10.1371/journal.pone.0092929.g005
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Figure 6. TEM analysis of N. caninum-infected HFF cultures in the presence of 2.5 mM of inhibitor 1294 for 5 and 9 days. A–C illustrate
two distinct outcomes of treatment with 2.5 uM of compound 1294 for 5 days within the same cell. A shows two parasitophorous vacuoles (PV1 and
PV2) in a HFF cell. In B, the higher magnification view of PV1 reveals non-viable remnants of tachyzoite (tach), now largely embedded in a solid matrix
(*), and as indicated by arrows, the parasitophorous vacuole membrane has been replaced by a rather amorphous transition zone between PV1 and
the host cell cytoplasm. In C, PV2 displays a complex of still viable and presumably proliferating, but non-separating, parasites forming a large multi-
nucleated mass, with clearly discernable micronemes (mic), rhoptries (rho), dense granules (dg), and smaller nuclei (nuc). Note the large nuclear mass
(NUC) in the center with a large nucleolus marked by the bold arrow. In D, and at a higher magnification in E, a similar multinucleated complex is
shown after 9 days of treatment with compound 1294, also displaying a large nuclear mass (NUC), as well as rhoptries, micronemes, dense granules,
and an intact parasitophorous vacuole membrane. In F, a non-viable complex with tachyzoite remnants (tach) is shown after 9 days of treatment.
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Thus structural studies of CDPK enzymes in complex with BKIs
together with computational modeling have been useful in guiding
synthetic chemistry for lead optimization by predicting functional
groups needed to improve potency, selectivity and further optimize
PK/ADME properties.
We have experimental evidence that N. caninum is prevented
from invading the mammalian host cell when lead compound
1294 is added at the time of infection. By EM and light
microscopy, some parasites treated with 1294 after infection
appear viable, but appear to be unable to lyse the HFF host cells.
Absence of any extracellular tachyzoites 5 days after 1294
treatment of infected HFF culture is consistent with inhibition of
N. caninum egress. In normal cell culture, N. caninum tachyzoites lyse
or egress from their host cells at around 72 hours (3 days) after
infection [19], [33]. BKI inhibition of TgCDPK1 have been linked
to the process of invasion and egress of the mammalian host [31],
[34], thus what we are observing in N. caninum is consistent with
that observation in T. gondii.
Beside potential impediment of egress, TEM analysis of HFF
cultures infected with N. caninum tachyzoites prior to treatment
with compound 1294 for an extended length of time (up to 12
days), revealed major ultra-structural alterations in N. caninum
tachyzoites, but not in mammalian host cells. More precisely, the
data suggests additional effects of BKIs on molecular target(s) that
control(s) separation of tachyzoites during replication, which
results in either parasites dying off intracellularly, or seemingly
viable parasites forming large multinucleated complexes. In other
instances, these complexes also show signs of metabolic impair-
ment. To the best of our knowledge, there is no literature or
experimental evidence of NcCDPK1 or TgCDPK1 involvement in
transducing signals needed in metabolic pathways or cell division.
However, egress impediment induced stress from 1294 treatment
of N. caninum tachyzoite infected HFF cells could be a potential
indirect cause or unrelated to inhibition of NcCDPK1. It is also
possible that the difference in potency or phenotypic effect on N.
caninum versus T. gondii is due to the presence of a second target
kinase in N. caninum. Comparison of the respective genomes argues
against this, however. The most plausible off-target activity would
be recognition of another small-gatekeeper kinase. Seven such
kinases can be found in the N. caninum genome, but in each case
the protein is directly homologous (E value = e‘-100 or better) to a
T. gondii kinase whose sequence contains that same small
gatekeeper residue. While this does not rule out the possibility of
off-target activity, on balance, it seems more likely that N. caninum
is somewhat more sensitive than T. gondii to interference with the
targeted CDPK1. Previous study on ruthenium complexes had
shown that drug effects can clearly differ between T. gondii and N.
caninum [35]. Similarly, these observations may be further
phenotypic characteristics of NcCDPK1 inhibition suggesting a
potential functional divergence or an amplification of physico-
chemical role relative to TgCDPK1. When infected HFF were
treated with 1294 for 12 days, followed by passage by trypsiniza-
tion to remove the compound, proliferation of tachyzoites
resumed, indicating that the drug is not parasiticidal in vitro.
Rather the trypsin may release the viable tachyzoites, which can
re-establish infection. However, it is unclear what specific
percentage of intracellular tachyzoites was damaged due to the
prolonged exposure to 1294; it is only clear that some of the
tachyzoites are viable and can re-establish infection.
Compound 1294 was recently shown to be a highly selective
inhibitor for parasites’ CDPKs compared with 80 mammalian
kinases [23] presumably due to smaller gatekeeper residues in
CDPKs and other interactions in the CDPKs active sites [24].
Other enzymes in the N. caninum kinome with small gatekeeper
residues, that compound 1294 could potentially inhibit, include
NcCamK (NCLIV_046430) with an alanine gatekeeper, NcAGC
like kinase (NCLIV_016060) with a serine gatekeeper, NcROP like
kinase (NCLIV_030990) with a threonine gatekeeper, and
NcMAPK-3 (NCLIV_056080) with a serine gatekeeper.
NcMAPK-3 is a TgMAPK-1 (TGME49_312570) ortholog with
highly conserved kinase domain of .80% identity. TgMAPK-1
been shown to play some role in sister parasite T. gondii stress
response [36], cell division [37]. It is unclear to what extent
compound 1294 could impact these targets, but sensitivity is
postulated to be related to the size of the respective enzymes’
gatekeeper residue in the order alanine.serine.threonine.
Intracellular damage to tachyzoites may be concentration
dependent probably due to different levels of sensitivity of
prospective N. caninum off-target enzymes to compound 1294.
In addition to demonstrating the molecular and structural basis
of BKIs impact on the growth of N. caninum tachyzoites in cell
culture, this study provides essential fundamental evidence for
potential clinical relevance of 1294 in the management of N.
caninum infection. Although the in vitro data suggest reversible
effects on growth inhibition with the removal of drug pressure, the
clinical outcome in a mouse model of infection indicates that five
to ten days treatment results in an almost undetectable cerebral
parasite burden with appropriate length of treatment (Figure 7).
Barely detectable number of parasites in the brains of mice from
1294-treated groups at least 2 weeks after the end of treatment,
compared to the high levels of brain parasites in the control group,
strengthens the argument that 1294 is efficacious in vivo despite not
Note the difference in electron density of the matrix of PVs containing non-viable parasites (B, F) compared to viable multinucleated complexes (C, D,
E). Bars in A= 5 mm; B= 0.8 mm; C= 0.9 mm; D= 2 mm; E = 0.7 mm; F = 0.9 mm.
doi:10.1371/journal.pone.0092929.g006
Figure 7. Compound 1294 treatment reduces cerebral parasite
load in N. caninum infected mice. Balb/c mice (8 animals per
experimental group), infected intraperitoneally with 56106 N. caninum-
b-gal tachyzoites, were treated with compound 1294 (50 mg/kg in
100 mL honey suspension). Group A (placebo) received honey for 5
days, group B received 1294 treatment starting at 3 days post infection
and continuing daily for 5 days; group C received the same as group B
but for 10 days. None of the mice exhibited clinical signs at 28 days
post-infection, after which the cerebral parasite load was assessed by
quantitative real time PCR.
doi:10.1371/journal.pone.0092929.g007
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being parasiticidal in in vitro. This is consistent with recent
observation of 1294 efficacy in the mouse cryptosporidiosis model
[17]. Although we cannot prove there was no regrowth of N.
caninum in the mouse model after 1294 dosing, the very low
parasite counts over 2 weeks after dosing with 1294 (Figure 7) is
good evidence that in vivo regrowth was minimal or immunologic
containment was established after the end of dosing. The reduced
numbers of N. caninum tachyzoites in the brains of treated mice is
evidence that compound 1294 crosses the blood-brain barrier in
sufficient concentration to be useful in clinical cases. Indeed, our
unpublished studies have shown that 25 to 33% of the plasma
levels of 1294 can be found in brain tissue of mice given a single
dose of 1294. Favorable pharmacokinetic and pharmacodynamic
properties of compound 1294 [23] combined with an immuno-
logic response, is likely to facilitate a more effective and complete
clearance of parasites in vivo compared to the in vitro situation.
Overall, the prospect of a broad-spectrum anti-apicomplexan
agent with no mammalian toxicity profile is quite exciting.
Although further studies will be needed to fully elucidate the
molecular target(s) of 1294, it seems that its role of inhibiting the
host cell invasion and egress process is only one of its many
functions.
Materials and Methods
Cloning and Protein Production
A truncated coding region of cdpk1 (NCLIV_011980) gene
(nucleotide base 6421521) was amplified from N. caninum Liver-
pool strain cDNA using the primers LICNcCDPK1_G23Fwd (59-
GGG TCC TGG TTC GGG GGC CGC CGG TGG AGC
GGG AGA CAA GCT CCA TGC GAC G -39) and
LICNcCDPK1_Rv (59- CTT GTT CGT GCT GTT TAT TAG
TTT CCG CAA AGC TTC AGG AGC ATT TGC TGA AAC -
39). The PCR product was cloned into the ligation independent
cloning (LIC) site of expression vector pAVA0421 containing a
cleavable 3C protease N-terminal 6-histidine tag and expressed in
Rosetta Escherichia coli (DE3) strain (Novagen, USA) using Studier
auto-induction protocols at 20uC [38]. Soluble recombinant
protein was purified on a Ni2+-NTA affinity (Qiagen, Valencia,
CA) column in binding buffer composed of 20 mM HEPES pH
7.25, 500 mM NaCl, 5% glycerol, 30 mM imidazole, 0.5%
CHAPS, and 1 mM TCEP. The protein was eluted with the same
buffer supplemented with 250 mM imidazole and further purified
by size-exclusion chromatography as previously described [39].
Activity Assay
Protein kinase activity of recombinant NcCDPK1 and inhibition
of its kinase phosphorylation properties by BKIs was measured in
a non-radioactive assay using Kinase-Glo luciferase reagent
(Promega, Madison, WI). This luminescence based assay measures
kinase activity in the presence or absence of inhibitors by reporting
changes in initial ATP concentration after NcCDPK1 phosphor-
ylation of biotinylated Syntide-2 peptide substrate (Biotin-C6-
PLARTLSVAGLPGKK) (BioSyntide-2) (American Peptide Com-
pany, Inc. Sunnyvale, CA) [15], [40]. Enzyme activity assays in
the presence of 40 mM BioSyntide-2 and 3.3 nM recombinant
NcCDPK1 with or without inhibitor(s) were performed in a
buffered solution containing 20 mM HEPES (pH 7.5), 0.1% BSA,
10 mM MgCl2, 1 mM EGTA, 2 mM CaCl2. The reaction was
initiated by the addition of 10 mM ATP and incubated for 90
minutes at 30uC. Changes in initial ATP concentration was
evaluated as a luminescence readout using a MicroBeta2 multi-
label plate reader (Perkin Elmer, Waltham, MA). Results were
converted to percent inhibition and IC50 values (the concentration
of compound that led to 50% inhibition of enzyme activity) were
calculated using non-linear regression analysis in GraphPad Prism
(GraphPad Software, La Jolla, CA) [16], [22].
Protein Crystallization
Diffraction quality crystals of NcCDPK1 were grown after
protein was gathered by Ni2+-NTA affinity chromatography,
treated with 20 mM EGTA (incubated on ice for 1 hour), and
further purified by size exclusion and an anion exchange column.
The protein solution used for crystallization contained 25 mM
HEPES pH 7.0, 500 mM NaCl, 5% glycerol, 5 mM DTT,
0.025% azide (protein buffer), 20 mM EGTA and ,3 mg ml21
protein. Crystals were grown by vapor-diffusion equilibration
against a reservoir containing 0.2 M ammonium sulfate, 0.1 M Bis
Tris (pH 5.1–5.6), 25–31% (v/v) PEG 3350 and 5 mM DTT. For
growing inhibitor co-crystals, 20 mM inhibitor in 100% DMSO
was diluted in 0.5 M EGTA and protein buffer, and subsequently
mixed with protein solution to a final concentration of 200 mM
inhibitor, 20 mM EGTA and 1% DMSO. One microliter (1 mL)
protein-inhibitor solution and 1 mL reservoir solution were mixed
for crystal growth at room temperature. In order to find optimal
growth conditions a matrix was used with steps of 1% difference in
PEG 3350 concentration and of 0.1 pH unit.
X-ray Diffraction and Crystal Structure Determination
Crystals of NcCDPK1 alone and cocrystallized in complex with
inhibitors formed in space group P21 with nearly isomorphous
lattice packing. Diffraction images were collected at SSRL
beamline 12-2 using X-rays with wavelength 0.9794 A˚ and
processed using the programs Mosflm [41] and Aimless [42].
The apo NcCDPK1 crystal diffracted to a resolution of 2.05 A˚.
Crystals of inhibitor complexes diffracted to resolutions between
2.6 A˚ and 3.1 A˚. An initial structural model was developed by
molecular replacement starting from a structure of the homolo-
gous CDPK1 from T. gondii followed by alternating manual
rebuilding in Coot [43] with automated refinement in Refmac
[44]. The refined model of the apo structure had crystallographic
residuals R = 0.20 Rfree = 0.26, with no residues in disallowed
regions of conformational space (Q;y). Individual structural models
for the lower resolution inhibitor complexes were developed by
manually adjusting secondary structure elements to account for
imperfect isomorphism followed by automated refinement in
Refmac using strong ‘‘jellybody’’ restraints in order to maintain
the good stereochemistry of the higher resolution starting model.
The inhibitors were placed into difference electron density at the
active site and included with the protein model during the final
round of refinement. Crystallographic statistics for data and model
quality for the structures of apo NcCDPK1and complexes with
inhibitors RM-1–132 (15n) [22] and 1294 (15o) [22] are given in
Table S1 and Figure S1 and S2 in File S1. The corresponding
PDB accession codes for these structures are 4m97, 4mxa, and
4mx9.
Small Angle X-ray Scattering
Solution small angle X-ray scattering (SAXS) was measured
from NcCDPK1 at concentrations of 0, 3, 6, and 12 mg/ml in a
buffer containing 500 mM NaCl, 5% glycerol, 25 mM HEPES
and either 1 mM CaCl2 or 1 mM EGTA. The scattering
experiments were performed at SSRL beamline 4–2 using
11 keV X-rays and a sample-to-detector distance of 170 cm. No
evidence for protein aggregation in either the low or high calcium
condition was found from comparing curves at different protein
concentrations. The SASTBX package [45] was used to analyze
scattering curves and to derive a low-resolution model for the
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conformations of the calcium-bound and calcium-free states in
solution. We have initiated a deposition request for the SAXS data
to the Bioisis project.
In vitro efficacy studies
Short term assays - simultaneous infection and BKI-
treatments. Transgenic N. caninum tachyzoites expressing beta-
galactosidase under a constitutive promoter (N. caninum-b-gal) were
grown in Vero cells and were separated from host cell components
as previously described [46]. Human foreskin fibroblasts (HFF) at
56103 cells per well in phenol-red free culture medium were
incubated at 37uC with 5% CO2 and were grown to confluence in
a 96-well plate. Just prior to infection, the inhibitors were added at
a final concentration of 2.5 mM for initial experiments and ranging
between 0.5 nM and 2.5 mM for EC50 determinations (the
effective concentration to reduce proliferation by 50%), or DMSO
as a control. Cultures were infected with N. caninum-b-gal
tachyzoites (16103 per well). After three days at 37uC/5% CO2,
plates were centrifuged at 500 g, medium was removed, and cell
cultures were lysed in PBS containing 0.05% Triton-X-100. After
addition of 10 mL of 5 mM chlorophenol red-b-D-galactopyrano-
side (CPRG; Roche Diagnostics, Rotkreuz, Switzerland) dissolved
in PBS, the absorption shift was measured at 570 nm wavelength
at various time points on a VersaMax multiplate reader (Bucher
Biotec, Basel, Switzerland). The activity, measured as the release
of chlorophenol red over time, was proportional to the number of
life parasites down to 50 per well as determined in pilot assays.
EC50 values were calculated after the logit-log-transformation of
relative growth and subsequent regression analysis by the
corresponding software tool contained in the Excel software
package (Microsoft, Seattle, WA) [46].
Short term assays – BKI treatments pre- and post-
infection. A subsequent experiment to determine the effects of
lead BKI compound 1294 on N. caninum invasion of mammalian
cells was performed. Here, HFF cell monolayers grown in 96 well
plates were infected with 26104 tachyzoites and treated with
compounds 1294 or 1266 [16] (as a BKI control that inhibited
NcCDPK1 .250-fold less efficiently than 1294) at a final
concentration of 5 mM per well at the time of initiation of
infection, as well as after 60, 90 and 115 minutes after addition of
tachyzoites. Control wells with equal volume of DMSO were also
included per reaction plate. Two hours after initiating the
experiment, the cells were washed. Selected untreated assay plates
were treated with 1294 for 60 minutes after the initial wash with
medium. All the assay plates were incubated for one hour before a
final wash and reading the beta-galactosidase activity.
Long term treatment with compound 1294. HFF mono-
layers were grown in 24 well tissue culture flasks, and were infected
with 16104 N. caninum tachyzoites for 2 hours, followed by addition
of compound 1294 (2.5 mM). Prolonged treatments for up to 12
days were carried out, with medium changes and addition of fresh
drug every 3 days. For some experiments, 1294-treated N. caninum-
infected monolayers were trypsinized after 12 days and cultures
were split into two, one further maintained in the presence of 1294
and the other one in the absence of the compound for up to 5 days.
For transmission electron microscopy (TEM), similar assays were
carried out using HFF monolayers grown in T25 tissue culture flasks
and infected with 56105 N. caninum tachyzoites. After selected time
points, cells were fixed and processed as described below.
TEM analysis of N. caninum-infected HFF treated with
compound 1294
Infected and 1294-treated cultures maintained in T25 tissue
culture flasks were processed for TEM at different time points after
infection (1, 3, 5 and 9 days) as described earlier [47], [48].
Infected cultures with no compound treatment were used as
controls. Fixation was carried out in 100 mM sodium cacodylate
buffer (pH 7.3) for 2 hours at room temperature, followed by post-
fixation in 2% osmium tetroxide in cacodylate buffer for 2 hours.
Following washes in water and pre-staining in saturated uranyl
acetate solution in water for 30 minutes, specimens were rinsed in
water, dehydrated in ethanol and embedded in Epon 812 resin as
previously described [19], [20]. The resin was polymerized at
60uC overnight, and ultrathin sections were cut on a Reicher &
Jung microtome, placed onto a formvar-coated grid and stained
with uranyl acetate and lead citrate. Specimens were viewed on a
Phillips EM 400 transmission electron microscope operating at
60 kV.
In vivo effects of 1294 treatment in N. caninum infected
Balb/c mice
Twenty-four female Balb/c mice between 8 and 9 weeks of age
were purchased from Charles River Laboratories (Sulzheim,
Germany) and were maintained in a common room under
controlled temperature and a 14 hour dark/10 hour light cycle
with food and water ad libitum according to the animal welfare
legislation of the Swiss Veterinary Office. At day zero, mice were
randomly caged into 3 experimental groups of 8 mice. Enzyme-
linked immunosorbent assay (ELISA) was carried out to ensure
that mice were serologically Neospora-negative [49]. Compound
1294 was initially formulated in honey for oral application as
described in Ku¨ster et al [50], at a dose of 50 mg/kg in 100 mL
suspension for both prophylactic and post-infection treatments.
The following oral treatments by standard gavage were carried
out: Experimental group A received honey only (daily placebo
treatment for 5 days), starting at 2 hours prior to infection; group
B received 1294 treatment starting at 3 days post infection and
continuing daily for 5 days; group C received the same as group B
but for a duration of 10 days. Infection was carried out by intra-
peritoneal inoculation of 56106 freshly isolated N. caninum-b-gal
tachyzoites in 100 mL medium. The experiments were terminated
28 days after infection. Mice were euthanized, brain tissues were
collected, and the cerebral parasite load was evaluated by
quantitative real time-PCR specific for N. caninum [46], [49].
Statistics
Statistical analysis of the results was performed with suitable
tools from the open source software package R. Differences
exhibiting p values of ,0.01 were considered significant. IC50
values were calculated after the logit-log-transformation of the
relative growth (RG; control = 1) according to the formula ln
(RG/(1-RG)) = a6ln(drug concentration) +b followed by regres-
sion analysis.
Ethics Statement
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VA, USA, http://www.atcc.org/products/all/SCRC-1041.aspx).
Experimental animals were maintained according to the animal
welfare legislation of the Swiss Veterinary Office and Institutional
Animal Care and Use Committees (IACUC). Facilities and
procedures for maintenance of experimental animals are fully
accredited by the American Association for Laboratory Animal
Care (AALAC) and approved by the University of Washington
IACUC under protocol number 2154-01.
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Supporting Information
File S1 Combined file of supporting figures and tables.
Table S1: Data collection and refinement statistics. Figure S1:
Electron density for compound 1294 (15o) in the active site of
NcCDPK1. Green density cages are difference electron density
from an initial map calculated prior to adding the inhibitor to the
structural model (3 sigma contours). Blue density cages are mFo-Fc
density after refinement of the protein and inhibitor. Figure S2:
Electron density for compound RM-1-132 (15n) in the active site
of NcCDPK1. Green density cages are difference electron density
from an initial map calculated prior to adding the inhibitor to the
structural model (3 sigma contours). Blue density cages are mFo-Fc
density contoured at 2.5 sigma after refinement of the protein and
inhibitor. The faint purple trace is a superposition of the same
compound as bound in the active site of the homologous
TgCDPK1.
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